v
Search
Advanced Search

Publications > Journals > Chronic Metabolic Diseases > About the journal

About the journal
Aims and Scope

Chronic Metabolic Diseases (CMD) is dedicated to advance our knowledge of the epidemiology, pathophysiology, prevention, and treatment of chronic metabolic diseases. We publish works from basic biomedical to translational and clinical research on metabolism.  

CMD’s scope includes obesity, diabetes, fatty liver, atherosclerosis, osteoporosis, dyslipidemia, and gout. Elucidating metabolic changes in tumorigenesis and ageing are also welcome, which sheds light on identifying novel pharmacological targets for cancer or ageing. To promote cross-disciplinary research and collaboration, we publish works of interest to researchers both in the area but also outside the immediate field.

Topics of particular interest include but are not limited to: 

  • Epidemiological/environmental factors of chronic metabolic diseases
  • Hormonal, neuronal, immunological or microbial regulation of chronic metabolic diseases
  • Diet, nutrition, and nutraceuticals
  • New strategies to establish models
  • Novel methods
  • Inter-tissue crosstalk
  • Microbiome research
  • Novel discoveries of biomarkers
  • Novel theories and mechanisms
  • Novel pharmacological targets
  • Crosstalk between metabolism and immunology in chronic metabolic diseases
  • OMICS and muti-OMICS studies
  • Evidence-based medicine
Open Access

Chronic Metabolic Diseases (CMD) adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are subject to the same rigorous peer-review and quality control as in scholarly subscription journals.

CMD recognizes the distinct advantages of using an open access publication model to timely disseminate innovative and important research findings. Unrestricted free access to our publications is anticipated to foster intellectual discourse across geographic and disciplinary boundaries. To support the success of our open access approach, we ensure the integrity and high quality of research published in our journal by practicing a rigorous peer review process and by following strict guidelines for ethics in publication and in conduct of the scientific process.

Publication Criteria

All manuscripts submitted to CMD must meet the following criteria for publication:

  • Topics with timely relevance to the general field or specialties in basic and clinical medicine;
  • A must-have section of “hypothesis/ future direction/ prospect/ prediction” included for all research and review articles;
  • Results and findings that have not been previously published elsewhere;
  • Research performed with adherence to accepted global standards for ethics in the scientific process;
  • Ethical reporting of data to protect the rights and privacy of study participants;
  • Appropriate statistical analyses, with sufficient descriptions of all statistical methods used;
  • Conclusions supported by the data presented;
  • All funding sources and their roles cited;
  • For clinical trials, the registration number cited;
  • Manuscript written in standard American (US) English and formatted according to the journal-specific guidelines;
  • No instances of textual plagiarism, including ‘text recycling/self-plagiarism”.
Publishing Schedule
CMD currently publishes 4 issues a year, in March, June, September and December.
Indexing Services
Journal Metrics
Revenue Sources
CMD adopts the open access publishing model. Revenues are generated from article processing charges (APC), permission fees, and reprints.
Ownership
CMD is owned and published by Xia & He Publishing Inc.
Contact us
Editorial Office

Managing Editor: Amber Dong
Postal Address: Room 505, Building B1, Bio-innovation Park, No. 666 High-tech Road, East Lake High-tech Development Zone, Wuhan, China

Publisher 

Xia & He Publishing Inc.
Tel: +1-409-420-2868 

US Office
Address: 14090 Southwest Freeway, Suite 300, Sugar Land, Texas 77478, USA

China Office
Address: Room 505, Building B1, Bio-innovation Park, No. 666 High-tech Road, East Lake High-tech Development Zone, Wuhan, China
Back to Top